Deferasirox is an orally active, once-daily iron chelator used to treat chronic iron overload in patients receiving regular blood transfusions. This guide summarises what deferasirox is, how it works, who it is for, and how it is administered - oriented toward healthcare professionals, regulatory teams and pharmaceutical procurement.
What is Deferasirox? #
Deferasirox is a synthetic, small-molecule iron chelator of the triazole class. It is designed to bind ferric iron (Fe3+) selectively, neutralise its redox activity, and promote elimination via bile. Two molecules of deferasirox wrap around a single iron ion in a 2:1 ligand-to-metal complex, which is taken up by the liver and excreted in faeces.
Deferasirox is administered orally. The dispersible tablet formulation - taken once daily after dispersion in water or juice - has been a cornerstone of long-term iron-chelation therapy, supplanting parenteral chelators that required overnight subcutaneous infusion.
Why Is Iron Chelation Necessary? #
Each unit of packed red blood cells delivers approximately 200 mg of elemental iron. Patients with beta-thalassemia major, sickle-cell disease, myelodysplastic syndromes and other transfusion-dependent anemias often require lifelong transfusion support. Without effective chelation, iron deposits in liver, heart, pancreas and pituitary - causing cirrhosis, cardiomyopathy and endocrine failure. Iron chelation has therefore been one of the most important advances in supportive care for these populations.
How Does Deferasirox Work? #
Deferasirox is a tridentate chelator: each molecule contributes three coordination atoms. Two molecules surround one Fe3+ ion to form a redox-inactive hexacoordinate complex. The drug is highly protein-bound (~99%) and circulates in plasma where it intercepts non-transferrin-bound iron. The chelator-iron complex is then excreted via the bile.
Who Takes Deferasirox? #
- Patients with beta-thalassemia major receiving frequent transfusions
- Patients with sickle-cell disease and chronic transfusion programmes
- Selected patients with MDS and other rare transfusion-dependent anemias
- Non-transfusional iron overload syndromes where locally approved
How Is Deferasirox Administered? #
The DEFRATAJ dispersible tablet is dropped into 100-200 ml of water, orange juice or apple juice, stirred until fully dispersed, and drunk immediately. The glass is rinsed with extra liquid that is also consumed. Administration is on an empty stomach, at least 30 minutes before food, at the same time each day.
Doses are weight-based, typically starting around 20 mg/kg/day with the dispersible formulation, adjusted in 5-10 mg/kg increments based on serum ferritin trend, liver iron concentration measurements, renal/hepatic monitoring and tolerability.
Safety: Key Points #
Common side effects include GI symptoms (nausea, diarrhoea), mild skin rash, and mild laboratory rises in serum creatinine and liver enzymes. Serious reactions include renal and hepatic dysfunction (occasionally severe), GI hemorrhage in elderly patients, cytopenias in MDS patients, and rare but serious cutaneous reactions including SJS, TEN and DRESS. Patients are monitored regularly with renal, hepatic and ferritin testing.
Procurement Considerations #
For tender agents, hospital pharmacies and distributors, deferasirox supply decisions are usually informed by:
- WHO-GMP / quality status of the manufacturer
- CTD dossier readiness for the destination market
- Strength availability across 100/125/250/400/500 mg dispersible tablets
- Pack format flexibility (blister, HDPE, custom)
- Lead time and supply reliability
- Total landed cost rather than ex-works price alone
Conclusion #
Deferasirox transformed iron-chelation therapy by converting an overnight infusion into a once-daily oral regimen. For ministries of health, hospital pharmacies and distributors, partnering with a WHO-GMP manufacturer such as Taj Pharma - producer of DEFRATAJ in five strengths - provides regulatory confidence, supply reliability and competitive economics for long-term patient programmes.